Wells Fargo & Company (NYSE:WFC) Chief Financial Officer Mike Santomassimo said the bank continues to see strong consumer spending, healthy credit trends and expanding business activity as it pursues growth following the removal of its asset cap.
Speaking at a financial conference, Santomassimo sai
On Sept. 14, 2026, CEO Brian Moynihan flagged weaker trading performance and softer dealmaking fees, keeping investors focused on capital-markets sensitivity.
Veeva Systems (NYSE:VEEV) is positioning artificial intelligence as an incremental growth opportunity beyond its previously stated goal of reaching $6 billion in revenue by 2030, according to executives speaking at a Wells Fargo healthcare technology event.
Paul Shawah, Veeva’s EVP of Commercial St
Biogen (NASDAQ:BIIB) executives said the company is focused on diversifying beyond its historical neurology concentration, advancing a broader late-stage pipeline and managing expenses as it seeks to return to growth.
Speaking at a Wells Fargo conference, Chief Financial Officer Robin Kramer said B
Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance.
Susie Lisa, the company’s head of investor relations, s
Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance.
Ryan Crowe, senior vice president of investor relations and strategic ana
Intuitive Surgical (NASDAQ:ISRG) executives said the company remains focused on global procedure growth, while acknowledging a recent deceleration in U.S. procedures and policy-related uncertainty affecting hospitals.
Speaking at a Wells Fargo conference, Executive Vice President, CFO and Enterpris
Amgen (NASDAQ:AMGN) executives highlighted growth across its key commercial products, progress in late-stage development programs and a continued focus on profitability and cash returns during a Wells Fargo biotech and pharma discussion.
Chief Financial Officer Thomas Dittrich, who recently returne
OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development.
Speaking
Caterpillar (NYSE:CAT) Chairman and CEO Joe Creed said the company has started 2026 with strong demand across its three operating segments, supported by power-generation activity, construction equipment sales and improving orders in resource industries.
Speaking at a Wells Fargo Securities event, C
Gilead Sciences (NASDAQ:GILD) Chief Medical Officer Dietmar Berger outlined the company’s priorities across HIV, oncology and inflammation at the Wells Fargo conference, describing a portfolio that has expanded through internal development and acquisitions and is now entering a period of prioritizat
Johnson & Johnson (NYSE:JNJ) MedTech Chairman Tim Schmid said the company remains confident it is delivering growth at the high end of its previously stated 5% to 7% operational market-growth range for the 2022 through 2027 period, citing a portfolio shift toward cardiovascular products, operating-m
AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit i
Editas Medicine (NASDAQ:EDIT) is preparing to begin a first-in-human study of EDIT-401, an in vivo CRISPR-edited medicine designed to lower LDL cholesterol in patients with heterozygous familial hypercholesterolemia, Chief Executive Officer Gilmore O’Neill said during a Wells Fargo discussion.
O’Ne
Medtronic (NYSE:MDT) executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.
Speaking at the Wells Fargo Healthcare Conference, Chairman and Chief
McKesson (NYSE:MCK) discussed its planned $2.25 billion acquisition of Precision Medicine Group, first-quarter operating trends and capital-allocation priorities during a presentation with Wells Fargo analyst Stephen Baxter.
The company said Precision Medicine Group would expand two areas it has id
In the past few months, investment banks have updated year end views on gold (“Au”) to US$4,500-$5,100/oz vs. the current price of ~$4,380. For example, Go
